Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook
Abstract Immunotherapy (IO) has revolutionized the therapy landscape of non-small cell lung cancer (NSCLC), significantly prolonging the overall survival (OS) of advanced stage patients. Over the recent years IO therapy has been broadly integrated into the first-line setting of non-oncogene driven N...
Main Authors: | Lena Horvath, Bernard Thienpont, Liyun Zhao, Dominik Wolf, Andreas Pircher |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-09-01
|
Series: | Molecular Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12943-020-01260-z |
Similar Items
-
Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for NSCLC
by: Alessandro Rossi, et al.
Published: (2021-08-01) -
Recent Advances in Immunotherapy in Metastatic NSCLC.
by: Pranshu Bansal, et al.
Published: (2016-11-01) -
Editorial: Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine
by: Barbara Melosky
Published: (2017-12-01) -
Tumor Endothelial Cells (TECs) as Potential Immune Directors of the Tumor Microenvironment – New Findings and Future Perspectives
by: Laurenz Nagl, et al.
Published: (2020-08-01) -
Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
by: Yi C, et al.
Published: (2019-09-01)